Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease

BACKGROUND: Registration authorities evaluate effects of new medicines for chronic obstructive pulmonary disease (COPD) on airway obstruction, dyspnea, health status and exacerbations. To establish clinical relevance, minimal clinically important differences (MCIDs) are used. The aim of this study w...

Descripción completa

Detalles Bibliográficos
Autores principales: Dankers, Marloes, Nelissen-Vrancken, Marjorie H. J. M. G., Surminski, Sara M. K., Lambooij, Anke C., Schermer, Tjard R., van Dijk, Liset
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016298/
https://www.ncbi.nlm.nih.gov/pubmed/32116657
http://dx.doi.org/10.3389/fphar.2019.01519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016298/
https://www.ncbi.nlm.nih.gov/pubmed/32116657
http://dx.doi.org/10.3389/fphar.2019.01519

Ejemplares similares